Literature DB >> 9055798

Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.

I Litvan1, G Campbell, C A Mangone, M Verny, A McKee, K R Chaudhuri, K Jellinger, R K Pearce, L D'Olhaberriague.   

Abstract

The difficulty in differentiating progressive supranuclear palsy (PSP, also called Steele-Richardson-Olszewski syndrome) from other related disorders was the incentive for a study to determine the clinical features that best distinguish PSP. Logistic regression and classification and regression tree analysis (CART) were used to analyse data obtained at the first visit from a sample of 83 patients with a clinical history of parkinsonism or dementia confirmed neuropathologically, including PSP (n = 24), corticobasal degeneration (n = 11), Parkinson's disease (PD, n = 11), diffuse Lewy body disease (n = 14). Pick's disease (n = 8) and multiple system atrophy (MSA, n = 15). Supranuclear vertical gaze palsy, moderate or severe postural instability and falls during the first year after onset of symptoms classified the sample with 9% error using logistic regression analysis. The CART identified similar features and was also helpful in identifying particular attributes that separate PSP from each of the other disorders. Unstable gait, absence of tremor-dominant disease and absence of a response to levodopa differentiated PSP from PD. Supranuclear vertical gaze palsy, gait instability and the absence of delusions distinguished PSP from diffuse Lewy body disease. Supranuclear vertical gaze palsy and increased age at symptom-onset distinguished PSP from MSA. Gait abnormality, severe upward gaze palsy, bilateral bradykinesia and absence of alien limb syndorme separated PSP from corticobasal degeneration. Postural instability successfully classified PSP from Pick's disease. The present study may help to minimize the difficulties neurologists experience when attempting to classify these disorders at early stages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055798     DOI: 10.1093/brain/120.1.65

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  28 in total

1.  Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia.

Authors:  Christopher Kobylecki; Matthew Jones; Jennifer C Thompson; Anna M Richardson; David Neary; David M A Mann; Julie S Snowden; Alexander Gerhard
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

2.  Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study.

Authors:  Rana A Eser; Alexander J Ehrenberg; Cathrine Petersen; Sara Dunlop; Maria B Mejia; Claudia K Suemoto; Christine M Walsh; Hima Rajana; Jun Oh; Panos Theofilas; William W Seeley; Bruce L Miller; Thomas C Neylan; Helmut Heinsen; Lea T Grinberg
Journal:  J Neuropathol Exp Neurol       Date:  2018-02-01       Impact factor: 3.685

3.  Factors that differentiate level of ambulation in hospitalised older adults.

Authors:  Steve R Fisher; James E Graham; Cynthia J Brown; Rebecca V Galloway; Kenneth J Ottenbacher; Richard M Allman; Glenn V Ostir
Journal:  Age Ageing       Date:  2011-09-09       Impact factor: 10.668

4.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 5.  Cortical excitability and neurology: insights into the pathophysiology.

Authors:  Radwa A B Badawy; Tobias Loetscher; Richard A L Macdonell; Amy Brodtmann
Journal:  Funct Neurol       Date:  2012 Jul-Sep

6.  Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease.

Authors:  Andrea Varrone; Marco Pagani; Elena Salvatore; Dario Salmaso; Valeria Sansone; Marianna Amboni; Flavio Nobili; Giuseppe De Michele; Alessandro Filla; Paolo Barone; Sabina Pappatà; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-24       Impact factor: 9.236

7.  Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study.

Authors:  Carlo Colosimo; Letterio Morgante; Angelo Antonini; Paolo Barone; Tania P Avarello; Edo Bottacchi; Antonino Cannas; Maria Gabriella Ceravolo; Roberto Ceravolo; Giulio Cicarelli; Rosa M Gaglio; Luisa Giglia; Francesco Iemolo; Michela Manfredi; Giuseppe Meco; Alessandra Nicoletti; Massimo Pederzoli; Alfredo Petrone; Antonio Pisani; Francesco E Pontieri; Rocco Quatrale; Silvia Ramat; Rossana Scala; Giampiero Volpe; Salvatore Zappulla; Anna Rita Bentivoglio; Fabrizio Stocchi; Giorgio Trianni; Paolo Del Dotto; Lucia Simoni; Roberto Marconi
Journal:  J Neurol       Date:  2009-08-09       Impact factor: 4.849

8.  Midbrain atrophy in subcortical ischemic vascular dementia.

Authors:  Young-Hee Sung; Ki-Hyung Park; Yeung-Bae Lee; Hyeon-Mi Park; Dong Jin Shin; Jea-Sul Park; Mi-Sun Oh; Hyeo-Il Ma; Kyung-Ho Yu; Suk-Yun Kang; Yun Joong Kim; Byung-Chul Lee
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

9.  MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease.

Authors:  Andrea Righini; Angelo Antonini; Roberta De Notaris; Elena Bianchini; Nicoletta Meucci; Giorgio Sacilotto; Margherita Canesi; Danilo De Gaspari; Fabio Triulzi; Gianni Pezzoli
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

10.  Anatomical correlates of sentence comprehension and verbal working memory in neurodegenerative disease.

Authors:  Serena Amici; Simona M Brambati; David P Wilkins; Jennifer Ogar; Nina L Dronkers; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.